



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**Datasheet for 009-001-T59S****STK9 protein-GST fusion****Overview**

<b>Description:</b>	STK9 recombinant protein-GST fusion protein - 009-001-T59S
<b>Item No.:</b>	009-001-T59S
<b>Size:</b>	20 µg
<b>Origin:</b>	Human
<b>Expressed in:</b>	Sf9 cells

**Product Details**

<b>Background:</b>	STK9 or CDKL5 is a member of Ser/Thr protein kinase family which has protein kinase activity and is associated with X-linked infantile spasm syndrome (ISSX), also known as X-linked West syndrome, and Rett syndrome (RTT). STK9 can control nuclear speckle morphology by regulating the phosphorylation state of splicing regulatory proteins, and may be involved indirectly in pre-mRNA processing, by controlling splicing factor dynamics (1). The mutations in the STK9 are a major cause of infantile spasms and early epileptic seizures in female patients, and of a later intractable seizure disorder (2). STK9 Protein is ideal for investigators involved in Signaling Proteins, Cellular Proteins, Cardiovascular Disease, ERK/MAPK Pathway, Neurobiology, PKA/PKC Pathway, and Ser/Thr Kinases research.
<b>Synonyms:</b>	CDKL5, EIEE2, ISSX, Cyclin-dependent kinase-like 5, STK9
<b>Species of Origin:</b>	Human
<b>Expressed in:</b>	Sf9 cells
<b>Type:</b>	Recombinant Protein

**Target Details**

<b>Gene Name:</b>	CDKL5
<b>Purity/Specificity:</b>	Recombinant human STK9 (CDKL5) (1-498) was expressed by baculovirus in Sf9 insect cells using an N-Terminal Glutathione-S-Transferase fusion protein. The purity was determined to be >90% by densitometry.
<b>Relevant Links:</b>	<ul style="list-style-type: none"><li>• <a href="#">NCBI - NM_003159</a></li></ul>

## Application Details

<b>Application Note:</b>	STK9 Protein is stored in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. STK9 Protein is suitable for use in Western Blot. Expect a band approximately ~84kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.
<b>Assay Dilutions:</b>	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
<b>WB:</b>	User Optimized

## Formulation

<b>Physical State:</b>	Liquid (sterile filtered)
<b>Concentration:</b>	0.1 µg/µL
<b>Buffer:</b>	See application note.

## Shipping & Handling

<b>Shipping Condition:</b>	Dry Ice
<b>Storage Condition:</b>	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
<b>Expiration:</b>	Expiration date is one (1) year from date of receipt.

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

